Advertisement
Sight Sciences, Inc.

Sight Sciences, Inc. Fundamental Analysis

SGHTNASDAQ
HealthcareMedical - Devices
$5.09
$0.46(10.02%)
U.S. Market is Open · 12:19
Advertisement

Sight Sciences, Inc. Fundamental Analysis

Sight Sciences, Inc. (SGHT) shows weak financial fundamentals with a PE ratio of -6.98, profit margin of -46.83%, and ROE of -59.10%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position32.47%
PEG Ratio-0.21
Current Ratio5.86

Areas of Concern

ROE-59.10%
Operating Margin-44.82%
We analyze SGHT's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -90.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-90.6/100

We analyze SGHT's fundamental strength across five key dimensions:

Efficiency Score

Weak

SGHT struggles to generate sufficient returns from assets.

ROA > 10%
-33.96%

Valuation Score

Excellent

SGHT trades at attractive valuation levels.

PE < 25
-6.98
PEG Ratio < 2
-0.21

Growth Score

Weak

SGHT faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

SGHT maintains a strong and stable balance sheet.

Debt/Equity < 1
0.76
Current Ratio > 1
5.86

Profitability Score

Weak

SGHT struggles to sustain strong margins.

ROE > 15%
-5909.57%
Net Margin ≥ 15%
-46.83%
Positive Free Cash Flow
No

Key Financial Metrics

Is SGHT Expensive or Cheap?

P/E Ratio

SGHT trades at -6.98 times earnings. This suggests potential undervaluation.

-6.98

PEG Ratio

When adjusting for growth, SGHT's PEG of -0.21 indicates potential undervaluation.

-0.21

Price to Book

The market values Sight Sciences, Inc. at 4.82 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.82

EV/EBITDA

Enterprise value stands at -9.43 times EBITDA. This is generally considered low.

-9.43

How Well Does SGHT Make Money?

Net Profit Margin

For every $100 in sales, Sight Sciences, Inc. keeps $-46.83 as profit after all expenses.

-46.83%

Operating Margin

Core operations generate -44.82 in profit for every $100 in revenue, before interest and taxes.

-44.82%

ROE

Management delivers $-59.10 in profit for every $100 of shareholder equity.

-59.10%

ROA

Sight Sciences, Inc. generates $-33.96 in profit for every $100 in assets, demonstrating efficient asset deployment.

-33.96%

Following the Money - Real Cash Generation

Operating Cash Flow

Sight Sciences, Inc. generates limited operating cash flow of $-25.34M, signaling weaker underlying cash strength.

$-25.34M

Free Cash Flow

Sight Sciences, Inc. generates weak or negative free cash flow of $-25.62M, restricting financial flexibility.

$-25.62M

FCF Per Share

Each share generates $-0.47 in free cash annually.

$-0.47

FCF Yield

SGHT converts -9.69% of its market value into free cash.

-9.69%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-6.98

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.21

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.82

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.30

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.76

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.86

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.59

vs 25 benchmark

ROA

Return on assets percentage

-0.34

vs 25 benchmark

ROCE

Return on capital employed

-0.39

vs 25 benchmark

How SGHT Stacks Against Its Sector Peers

MetricSGHT ValueSector AveragePerformance
P/E Ratio-6.9834.27 Better (Cheaper)
ROE-59.10%377.00% Weak
Net Margin-46.83%-42945.00% (disorted) Weak
Debt/Equity0.760.78 Neutral
Current Ratio5.865.54 Strong Liquidity
ROA-33.96%-162.00% (disorted) Weak

SGHT outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sight Sciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ